Alembic Pharmaceuticals Ltd shares surged more than 6% today after the company reported impressive financial results for the second quarter of FY25, reflecting strong business momentum and improved profitability. As of 2:38 PM, the shares were trading 5.92% higher at Rs 978.90.
The pharma major’s net profit climbed 21% year-on-year to ₹185 crore, up from ₹153 crore in the same quarter last year. This growth was driven by robust sales and better operational performance. Revenue rose 16% to ₹1,910 crore compared to ₹1,648 crore in Q2 FY24, supported by steady demand across key markets.
EBITDA grew 32% to ₹315.3 crore from ₹239.3 crore a year earlier, indicating higher efficiency and effective cost management. The EBITDA margin expanded to 16.5% from 14.5% in the previous year, showcasing significant improvement in the company’s profitability profile.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
